Led by seasoned biotech executives and renowned cardiovascular advisors, CFM Pharma’s team combines hands‑on clinical‑trial expertise with a robust licensing track record—providing the capabilities needed to steer VANADIS® through Phase 1B/2A trials and secure early‑stage pharmaceutical partnerships.

Lekhram Changoer is a seasoned biotech entrepreneur who has co‑founded multiple IP‑driven pharmaceutical companies and guided them from preclinical research all the way to product licensing. Over the past 20 years, he has built deep expertise in launching clinical trials, steering R&D pipelines, crafting strategic business plans, securing licensing agreements, and forging partnerships with pharma firms, CROs, GMP manufacturers, and academic institutions.

• MSc Organic Chemistry; BSc Analytical & Organic Chemistry

• 20+ years in pharma R&D, clinical development & commercialization

• Co‑founded three IP‑based biotechs; led product planning, global launches & licensing

A biochemist by training, Henk leverages his deep molecular science expertise to drive biotech innovation. He has extensive experience founding and scaling companies and translating laboratory discoveries into clinical products, with a strong focus on cardiology and acute‑care solutions.

• Broad expertise spanning cardiology, burn wounds, renal failure and metabolic disorders—and end‑to‑end drug development (diagnostics, PK/Tox, orphan drugs, delivery platforms).
• Inventor of FLOTEX‑C, an oral controlled‑release system enhancing drug safety and efficacy; named on eight patents, including oxygen‑release formulations and wound‑healing.
• Co‑founder and former CTO of CFM Pharma.

An operations and finance expert, David combines rigor with strategic acumen. He co‑architected CFM Pharma’s business plan, investor materials, and full financial infrastructure—drawing on a career that ranges from steering €100 million business units at Procter & Gamble to building GMP‑ready finance systems for fast‑growing life‑science ventures.

• Co‑creator of CFM Pharma’s strategic business plan, investor presentations, and legal‑financial framework; has raised over €100 M through targeted private and institutional rounds.
• Architect of FP&A, P&L management, and financial systems enabling GMP‑scale operations and rapid growth.
• Former European executive at Procter & Gamble, Ferro, and Royal Sanders; founded and led a consultancy that executed full‑scale turnarounds and built pan‑European distribution networks.

• Professor of Experimental Vascular Medicine, LUMC

• Fellow, American Heart Association (FAHA) & Established Investigator, Dutch Heart Foundation

• Board member, Dutch Atherosclerosis Society; expert in vascular surgery & microvascular regeneration

• Professor of Cardiology & Cardiovascular Gerontology, Newcastle University

• Honorary Consultant Interventional Cardiologist, Freeman Hospital

• Director, Cardio‑Immunology Lab, Translational & Clinical Research Institute